CellaVision AB
STO:CEVI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
CellaVision AB
Capital Expenditures
CellaVision AB
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
CellaVision AB
STO:CEVI
|
Capital Expenditures
-kr86.3m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
-25%
|
|
|
Elekta AB (publ)
STO:EKTA B
|
Capital Expenditures
-kr1.2B
|
CAGR 3-Years
10%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
|
S
|
Surgical Science Sweden AB
STO:SUS
|
Capital Expenditures
-kr49.3m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-42%
|
CAGR 10-Years
N/A
|
|
|
Getinge AB
STO:GETI B
|
Capital Expenditures
-kr1.3B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
Arjo AB (publ)
STO:ARJO B
|
Capital Expenditures
-kr419m
|
CAGR 3-Years
9%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
S
|
Stille AB
STO:STIL
|
Capital Expenditures
-kr20.6m
|
CAGR 3-Years
-37%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-35%
|
|
CellaVision AB
Glance View
CellaVision AB engages in the provision of automated microscopy systems in the field of hematology. The company is headquartered in Lund, Skane and currently employs 200 full-time employees. The company went IPO on 2007-05-28. The firm develops and sells digital solutions for medical microscopy, as well as products enabling blood cell analysis and morphology diagnosis. CellaVision AB’s product portfolio consists of analyzers for automated medical microscopy analysis and software applications designed for remote access, competency testing and education. The analyzers include such brands as CellaVision DM96 and CellaVision DM1200, whereas the software applications are divided into CellaVision Body Fluid Application, CellaVision Remote Review Software and CellaVision Competency Software, among others. The firm operates four subsidiaries, based in Sweden, Canada, the United States and Japan. In June 2014, CellaVision AB acquired technology platform from Clear Lake Medical Foundation.
See Also
What is CellaVision AB's Capital Expenditures?
Capital Expenditures
-86.3m
SEK
Based on the financial report for Dec 31, 2025, CellaVision AB's Capital Expenditures amounts to -86.3m SEK.
What is CellaVision AB's Capital Expenditures growth rate?
Capital Expenditures CAGR 10Y
-25%
Over the last year, the Capital Expenditures growth was -11%. The average annual Capital Expenditures growth rates for CellaVision AB have been -8% over the past three years , -21% over the past five years , and -25% over the past ten years .
